BioMarin Pharmaceutical | Spese Di Vendita E Di Amministrazione





Spese Di Vendita E Di Amministrazione Cambiamento Data
Acadia Pharmaceuticals USD 124.9M 1.24M 2025-09
Agios Pharmaceuticals USD 42.97M 1.7M 2025-12
Alnylam Pharmaceuticals USD 285.06M 22.47M 2025-12
Amgen USD 1.94B 237M 2025-12
Bayer EUR 3.4B 140M 2025-09
Biogen USD 545.2M 38.6M 2025-09
BioMarin Pharmaceutical USD 223.42M 8.86M 2025-09
Gilead Sciences USD 1.78B 425M 2025-12
Incyte USD 390.41M 61.33M 2025-12
Insmed USD 212.48M 26.11M 2025-12
Ionis Pharmaceuticals USD 86.56M 4.04M 2025-09
Moderna USD 308M 40M 2025-12
Neurocrine Biosciences USD 301.8M 10.2M 2025-12
PTC Therapeutics USD 87.2M 3.15M 2025-12
Puma Biotechnology USD 16.82M 8.15M 2024-09
Regeneron Pharmaceuticals USD 775M 117.2M 2025-12
Roche Holding CHF 7.28B 3.99B 2025-12
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Sanofi EUR 2.75B 455M 2025-12
Sarepta Therapeutics USD 77.11M 7.22M 2025-09
Ultragenyx Pharmaceutical USD 89M 2.38M 2025-12
United Therapeutics USD 152M 60.5M 2025-09
Vertex Pharmaceuticals USD 487M 41.9M 2025-12


BioMarin Pharmaceutical Spese Di Vendita E Di Amministrazione - Valori correnti, dati storici, previsioni, statistiche, grafici e calendario economico - Feb 2026.